Triple-negative breast cancer (TNBC), which accounts for approximately 10–15% of all breast cancers, refers to a specific subtype that tests negative for estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2) protein [1]. This evidence concerns the gene PGR and breast cancer.